Skip to main content
. 2014 Jul 21;111(31):11365–11370. doi: 10.1073/pnas.1411701111

Fig. 5.

Fig. 5.

Combination therapy in a xenograft model of ABC DLBCL. (A) Human TMD8 ABC DLBCL cells were established as a s.c. tumor in NOD/SCID mice and treated by i.p. injection with either vehicle or BET Inhibitor CPI203 (5 mg/kg). Mice were treated for 21 d, and tumor growth was measured as a function of tumor volume. (B) Human TMD8 ABC DLBCL cells were established as a s.c. tumor in CB17 SCID mice and treated by i.p. injection with vehicle, BET inhibitor CPI203 (5 mg/kg), BTK inhibitor ibrutinib (2 mg/kg), or with a combination of CPI203 and ibrutinib. Mice were treated for 12 d, and tumor growth was measured as a function of tumor volume. (C) Total RNA was extracted from xenograft biopsies. Human IL6, IL10, and MYC mRNA levels were measured by TaqMan RT Q-PCR. For each gene, the relative abundance was calculated vs. B2M values, arbitrarily set to 1,000. Error bars represent SEM. (A) n = 3 mice per group. (B) n = 9 mice per group. (C) n = 7 for vehicle group, n = 8 for combination group, and n = 9 for single-arm groups.